Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amitriptyline is a tricyclic antidepressant primarily used to treat major depressive disorder. It is also indicated for neuropathic pain syndromes (such as post-herpetic neuralgia), migraine and tension headache prophylaxis, and sometimes for eating disorders or nocturnal enuresis in children. Amitriptyline works by increasing the levels of certain neurotransmitters in the brain—mainly serotonin and norepinephrine—which helps regulate mood and pain perception[2][4][6]. The drug has strong anticholinergic effects, which contribute to its sedative properties but also increase side effects such as dry mouth, drowsiness, constipation, and weight gain[2][7]. Due to its side effect profile and toxicity risk in overdose, it is generally considered a second-line therapy for depression and pain conditions[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amitriptyline.